Target antigens for therapeutic antibodies in oncology: Many candidates, few successes;Antigènes-cibles d'anticorps thérapeutiques en cancérologie: Beaucoup de candidats, peu d'élus

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Ceze, Nicolas ^a   Probst, Alicia ^a   Lecomte, Thierry ^a   Ohresser, Marc ^a   Paintaud, Gilles ^a   Watier, Hervé ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

Antigens; Receptors; Targeted therapies; Therapeutic antibodies

Indexed keywords

ADECATUMUMAB; ALEMTUZUMAB; ATLIZUMAB; BEVACIZUMAB; CETUXIMAB; DENOSUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LABETUZUMAB; MONOCLONAL ANTIBODY; OREGOVOMAB; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; VECTIBIX;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER THERAPY; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; LIPID MEMBRANE; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; DOWN-REGULATION; EPITOPES; IMMUNIZATION, PASSIVE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN;

EID: 36248967119     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0438     Document Type: Review

References (37)

1. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 ; 254 : 1643-7.
2. Goldstein NI, Prewett M, Zuklis K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995 ; 1 : 1311-8.
3. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol 2004 ; 15 : 1007-12.
4. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001 ; 38 : 17-23.
5. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splincing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990 ; 87 : 8602-6.
6. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor VIII enhances tumorogenicity in human breast cancer. Cancer Res 2000 ; 60 : 3081-7.
7. Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, et al. Identification of the epitope for the Epidermal Growth Factor-specific Monoclonal Antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004 ; 279 : 30375-84.
8. Johns TG, Mellman I, Cartwright GA, Ritter G, Old LJ, Burgess A, et al. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J 2005 ; 19 : 780-2.
9. Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, et al. Engineering and characterization of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7EGFR or amplified EGFR. Br J Cancer 2005 ; 92 : 1069-77.
10. Liebisch P, Eppinger S, Schopflin C, Stehle G, Munzert G, Dohner H, et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 2005 ; 90 : 489-93.
11. Duiker EW, Mom CH, De Jong S, Willemse PH, Gietema JA, Van Der Zee AG, et al. The clinical trail of TRAIL. Eur J Cancer 2005 ; 42 : 2233-40.
12. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis - inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 2006 ; 84 : 87-98.
13. Mac Dougall IC. CERA (continuous erythropoietin receptor activator) : a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005 ; 4 : 436-40.
14. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Nat Cancer Inst 2003 ; 95 : 851-67.
15. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti. HER2 monoclonal antibodies : scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003 ; 532 : 253-68.
16. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into erbB signaling from the structure of the erbB2-pertuzumab complex. Cancer Cell 2004 ; 5 : 317-28.
17. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003 ; 421 : 756-60.
18. Dikic I. Mechanisms controlling EGF receptor endocytosis and degradation. Biochem Soc Trans 2003 ; 31 : 1178-81.
19. 131I-labecuzumab after salvage resection of colorectal metastases in the liver : five-year safety and efficacy results. J Clin Oncol 2005 ; 23 : 6763-70.
20. Wu AM, Senter PD. Arming antibodies : prospects and challenges for immunoconjugates. Nat Biotechnol 2005 ; 23 : 1137-46.
21. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside : ways to improve rituximab efficacy. Blood 2004 ; 104 : 2635-42.
22. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998 ; 91 : 1644-52.
23. Maloney DG, Smith B, Rose A. Rituximab : mechanism of action and resistance. Semin Oncol 2002 ; 1(Suppl 2) : 2-9.
24. Zent CS, Chen JB, Kurten RC, Kaushal GP, Marie Lacy H, Schichman SA. Alemtuzumab (Campath 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004 ; 28 : 495-507.
25. Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fujii H. Cetuximab induce antibody dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2006 ; (sous presse).
26. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for the Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001 ; 276 : 6591-604.
27. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006 ; 24 : 2666-72.
28. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, et al. Levels of expression of CD52 in normal and leukemic B and T cells : correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998 ; 22 : 185-91.
29. Osuji N, Del Giudice I, Matutes E, Morilla M. Owusu. Ankomah K, Morilla R, et al. CD52 expression in T-cell large granular lymphocyte leukemia. Implications for treatmenr with alemtuzumab. Leuk Lymph 2005 ; 46 : 723-7.
30. Cragg MS, Morgan SM, Chan CHT, Morgan BP, Filatov AV, Johnson PWM, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003 ; 101 : 949-54.
31. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, et al. Novel third-generation humanized Type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 2006 ; 108 ; (abstract #229).
32. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003 ; 101 : 949-54.
33. Behr TM, Béhé M. Trastuzumab and breast cancer. N Engl J Med 2001 ; 345 : 995-8.
34. Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, de Cremoux P, Couturier J, et al. Herceptin, a monoclonal humanized antibody anti. HER2 : a major therapeutic progress in breast cancers overexpressing this oncogene? Bull Cancer 1999 ; 86 : 544-9.
35. Figlin RA, Belldegrun A, Crawford J, Lohner M, Roskos L, Yang XD, et al. ABX-EGF, a fully humanized anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer : phase I clinical results. Proc Am Soc Clin Oncol 2002 : 21 ; [abstract #35].
36. Schwartz G, Dutcher JP, Vogelzang NJ, Gallob J, Thompson J, Bukowski RM, et al. Phase II clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 2002 : 21 ; [Abstract #91].
37. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005 ; 7 : 301-11.